Sign up
Pharma Capital

Patrys wins another U.S. patent for its unique cancer antibody

The antibody has shown great promise in laboratory and animal testing.
Patrys has two technology platforms

Patrys Limited (ASX:PAB) has been granted a U.S. patent for its anti-cancer candidate PAT-LM1 for use in treating colon cancer metastasis.

Based in Melbourne, Patrys is focused on the development of antibodies as therapies for a range of different cancers.

Patrys has already secured eight patents across the PAT-LM1 families in three jurisdictions - the U.S., Europe and UK.

PAT-LM1 is a natural human antibody that has shown great promise in laboratory and animal testing as a potential treatment for multiple types of cancer like colon, lung, breast, ovary and pancreas.

The antibody attacks a protein called NONO which is expressed in 98% of over 200 different types of cancer cells screened.

NONO has been shown to play a role in modulating cell death and repair mechanisms and as a marker in estrogen receptor negative breast cancer tumours.

Patrys has two technology platforms, IgM monoclonal antibodies and a suite of nuclear penetrating antibodies for cancer therapy.

In March 2016, Patrys had licensed the exclusive rights to two nuclear-penetrating lupus antibodies for cancer therapy from Yale University.

Register here to be notified of future PAB Company articles
View full PAB profile View Profile

Patrys' shares halted

View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.